Sotyktu/Deucra Abstract Titles at ACR2022 10-14Nov2022 | BMY Message Board Posts


Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  10304 of 10562  at  9/21/2022 11:01:52 AM  by

grafzeppelin


 In response to msg 10303 by  Baltasar
view thread
Strong Buy

Re: Sotyktu/Deucra Abstract Titles at ACR2022 10-14Nov2022

 you are correct i am mixing the metaphor a bit so to speak, but i do think of gi intolerance - and it is significant - as safety though intolerance is more accurate.  nonetheless it really does limit usage and the dose escalation pack needed to initial treatment tacitly confirms its significance.  now as to deucra safety - lets not conflate the fda label language with what was seen in the trials (yes real world data is needed to confirm) which was really really good.  imho the label language is hangover from experience with the "classic jaks".  time will tell of course but i stand by my opinion i would try deucra first if i were a patient and conflict of interest disclosed, would prescribe it readily to my patients if i was still in practice.


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 4  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
10305 Re: Sotyktu/Deucra Abstract Titles at ACR2022 10-14Nov2022 Baltasar 8 9/21/2022 11:49:06 AM




Financial Market Data provided by
.
Loading...